PATENT CLAIM ANALYSIS

Application Number: 16079802
Application Type: Utility
Filing Date: 2018-08
Publication Date: 2019-02
Patent Classification: ["514", "330000"]

Abstract:
Provided are methods and compositions for treating cancers in patients carrying an IDH1 mutation or IDH2 mutation.

Claim (Index 28):
The compound for use of any one of  claims 25  to  27 , wherein the FLT3 inhibitor is selected from quizartinib (AC220), sunitinib (SU11248), sorafenib (BAY 43-9006), midostaurin (PKC412), lestaurtinib (CEP-701), crenolanib (CP-868596), PLX3397, E6201, AKN-028, ponatinib (AP24534), ASP2215, KW-2449, famitinib and DCC-2036.

Metadata:
- Claim Count in Document: 1.0
- Percentile: 96.0
- Lexical Diversity: 1.05882
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15368405', '15767822', '15368439', '15768462', '15125880']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.844101149324463
- 35 USC 102 Novelty (BERT): 0.5380375248372358
- Combined Prediction Score: 0.8134947868757403
- Mean Citation Score: 462.025804
- Max Citation Score: 504.7606
- Similarity Product: 296.2295527053356

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test